UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | December 20, 2010 |
MedQuist Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| New Jersey | 0-19941 | 22-2531298 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 1000 Bishops Gate Boulevard, Suite 300, Mount Laurel, New Jersey | | 08054-4632 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 856.206.4000 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07 Submission of Matters to a Vote of Security Holders.
The 2010 Annual Meeting of Shareholders of MedQuist Inc. (“MedQuist”) was held on December 20, 2010 (the “Annual Meeting”). At the Annual Meeting, the sole matter submitted to a vote of the holders of MedQuist’s common stock was a proposal to elect eight directors nominated by MedQuist’s Board of Directors.
Each of the eight nominees were elected as directors to hold office for a one-year term or until his successor is duly elected and qualified, with the following voting results:
| | | | | | | | | |
| Director Nominee | | Votes For | | Votes Withheld |
| Robert Aquilina | | | 29,126,862 | | | | 1,169,130 | |
| Frank Baker | | | 29,058,603 | | | | 1,237,389 | |
| Peter E. Berger | | | 29,056,203 | | | | 1,239,789 | |
| John F. Jastrem | | | 30,246,481 | | | | 49,511 | |
| Colin J. O’Brien | | | 30,247,084 | | | | 48,908 | |
| Warren E. Pinckert II | | | 30,227,079 | | | | 68,913 | |
| Michael Seedman | | | 29,056,203 | | | | 1,239,789 | |
| Andrew E. Vogel | | | 30,241,251 | | | | 54,741 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | MedQuist Inc. |
| | | | | |
| December 27, 2010 | | By: | | /s/ Mark R. Sullivan
|
| | | | |
|
| | | | | Name: Mark R. Sullivan |
| | | | | Title: General Counsel, Chief Compliance Officer & Secretary |
